Carlos F. Narváez

Dr. Carlos F. Narváez

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SSSanae Sasaki
Sanae Sasaki
MSMeghan Sullivan
Meghan Sullivan
CNCarlos F. Narváez
Carlos F. Narváez
THTyson H. Holmes
Tyson H. Holmes
DFDavid Furman
David Furman
XHXiao-Song He
Xiao-Song He
During seasonal influenza epidemics, disease burden is shouldered predominantly by the very young and the elderly. Elderly individuals are particularly affected, in part because vaccine efficacy wanes with age. This has been linked to a reduced ability to induce a robust serum antibody response. Here, we show that this is due to reduced quantities of vaccine-specific antibodies, rather than a lack of antibody avidity or affinity. We measured levels of vaccine-specific plasmablasts by ELISPOT 1 week after immunization of young and elderly adults with inactivated seasonal influenza vaccine. Plasmablast-derived polyclonal antibodies (PPAbs) were generated from bulk-cultured B cells, while recombinant monoclonal antibodies (re-mAbs) were produced from single plasmablasts. The frequency of vaccine-specific plasmablasts and the concentration of PPAbs were lower in the elderly than in young adults, whereas the yields of secreted IgG per plasmablast were not different. Differences were not detected in the overall vaccine-specific avidity or affinity of PPAbs and re-mAbs between the 2 age groups. In contrast, reactivity of the antibodies induced by the inactivated seasonal influenza vaccine toward the 2009 pandemic H1N1 virus, which was not present in the vaccine, was higher in the elderly than in the young. These results indicate that the inferior antibody response to influenza vaccination in the elderly is primarily due to reduced quantities of vaccine-specific antibodies. They also suggest that exposure history affects the cross-reactivity of vaccination-induced antibodies.

27 September 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
IBIrene Bosch
Irene Bosch
HPHelena de Puig
Helena de Puig
MHMegan Hiley
Megan Hiley
MCMarc Carré-Camps
Marc Carré-Camps
FCFederico Perdomo Celis
Federico Perdomo Celis
LGLee Gehrke
Lee Gehrke
A low-cost, equipment-free rapid antigen test distinguishes dengue virus serotypes and Zika virus in patient sera without detectable cross-reactivity.

1 May 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
EDEmily M. Deal
Emily M. Deal
KLKatharina Lahl
Katharina Lahl
CNCarlos F. Narváez
Carlos F. Narváez
EBEugene C. Butcher
Eugene C. Butcher
HGHarry B. Greenberg
Harry B. Greenberg
B cell–dependent immunity to rotavirus, an important intestinal pathogen, plays a significant role in viral clearance and protects against reinfection. Human in vitro and murine in vivo models of rotavirus infection were used to delineate the role of primary plasmacytoid DCs (pDCs) in initiating B cell responses. Human pDCs were necessary and sufficient for B cell activation induced by rotavirus. Type I IFN recognition by B cells was essential for rotavirus-mediated B cell activation in vitro and murine pDCs and IFN-α/β–mediated B cell activation after in vivo intestinal rotavirus infection. Furthermore, rotavirus-specific serum and mucosal antibody responses were defective in mice lacking functional pDCs at the time of infection. These data demonstrate that optimal B cell activation and virus-specific antibody secretion following mucosal infection were a direct result of pDC-derived type I IFN. Importantly, viral shedding significantly increased in pDC-deficient mice, suggesting that pDC-dependent antibody production influences viral clearance. Thus, mucosal pDCs critically influence the course of rotavirus infection through rotavirus recognition and subsequent IFN production and display powerful adjuvant properties to initiate and enhance humoral immunity.

28 February 2011 in Journal of Immunological Methods
Verified
Journal Article
Closed access
XHXiao-Song He
Xiao-Song He
SSSanae Sasaki
Sanae Sasaki
CNCarlos F. Narváez
Carlos F. Narváez
CZCaiqiu Zhang
Caiqiu Zhang
HLHui Liu
Hui Liu
HGHarry B. Greenberg
Harry B. Greenberg

15 December 2005 in Journal of Virology
Verified
Journal Article
Open access
PDF file
CNCarlos F. Narváez
Carlos F. Narváez
JAJuana Angel
Juana Angel
MFManuel Antonio Franco
Manuel Antonio Franco
We have previously shown that very few rotavirus (RV)-specific T cells that secrete gamma interferon circulate in recently infected and seropositive adults and children. Here, we have studied the interaction of RV with myeloid immature (IDC) and mature dendritic cells (MDC) in vitro. RV did not induce cell death of IDC or MDC and induced maturation of between 12 and 48% of IDC. Nonetheless, RV did not inhibit the maturation of IDC or change the expression of maturation markers on MDC. After treatment with RV, few IDC expressed the nonstructural viral protein NSP4. In contrast, a discrete productive viral infection was shown in MDC of a subset of volunteers, and between 3 and 46% of these cells expressed NSP4. RV-treated IDC secreted interleukin 6 (IL-6) (but not IL-1β, IL-8, IL-10, IL-12, tumor necrosis factor alpha, or transforming growth factor beta), and MDC released IL-6 and small amounts of IL-10 and IL-12p70. The patterns of cytokines secreted by T cells stimulated by staphylococcal enterotoxin B presented by MDC infected with RV or uninfected were comparable. The frequencies and patterns of cytokines secreted by memory RV-specific T cells evidenced after stimulation of peripheral blood mononuclear cells (PBMC) with RV were similar to those evidenced after stimulation of PBMC with RV-infected MDC. Finally, IDC treated with RV strongly stimulated naive allogeneic CD4+T cells to secrete Th1 cytokines. Thus, although RV does not seem to be a strong maturing stimulus for DC, it promotes their capacity to prime Th1 cells.

25 October 2008 in Virology
Verified
Journal Article
Closed access
OROlga Lucía Rojas
Olga Lucía Rojas
CNCarlos F. Narváez
Carlos F. Narváez
HGHarry B. Greenberg
Harry B. Greenberg
JAJuana Angel
Juana Angel
MFManuel Antonio Franco
Manuel Antonio Franco